siRNA-induced liver ApoB knockdown lowers serum LDL-cholesterol in a mouse model with human-like serum lipids

Journal of Lipid Research

Volumn 52, Issue 6, 2011, Pages 1084-1097

  Tadin Strapps, Marija ^a   Peterson, Laurence B ^b   Cumiskey, Anne Marie ^b   Rosa, Raymond L ^b   Mendoza, Vivienne Halili ^b   Castro Perez, Jose ^b   Puig, Oscar ^b   Zhang, Liwen ^b   Strapps, Walter R ^a   Yendluri, Satyasri ^a   Andrews, Lori ^a   Pickering, Victoria ^a   Rice, Julie ^a   Luo, Lily ^a   Chen, Zhu ^b   Tep, Samnang ^a   Ason, Brandon ^a   Somers, Elizabeth Polizzi ^b   Sachs, Alan B ^a   Bartz, Steven R ^a   Tian, Jenny ^b   Chin, Jayne ^b   Hubbard, Brian K ^b   Wong, Kenny K ^b   Mitnaul, Lyndon J ^b   more..

^a Sirna Therapeutics Inc   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cholesteryl ester transfer protein; Low density lipoprotein cholesterol; Low density lipoprotein receptor; Short interfering RNA

Indexed keywords

APOLIPOPROTEIN B; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; SMALL INTERFERING RNA; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CETP GENE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; GENE; HEMIZYGOTE; HETEROZYGOTE; LDLR GENE; LIPID LIVER LEVEL; LIPOPROTEIN BLOOD LEVEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; TRANSGENE;

ANIMALS; APOLIPOPROTEINS B; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CELL LINE, TUMOR; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, LDL; DISEASE MODELS, ANIMAL; FOUNDER EFFECT; GENE EXPRESSION PROFILING; GENE KNOCKDOWN TECHNIQUES; HEMIZYGOTE; HUMANS; LIPID METABOLISM; LIPOSOMES; LIVER; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NANOPARTICLES; RECEPTORS, LDL; RNA, MESSENGER; RNA, SMALL INTERFERING; TRIGLYCERIDES;

EID: 79956022523     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M012872     Document Type: Article

References (38)

1. Wouters, K., R. Shiri-Sverdlov, P. J. van Gorp, M. van Bilsen, and M. H. Hofker. 2005. Understanding hyperlipidemia and atherosclerosis: lessons from genetically modified apoe and ldlr mice. Clin. Chem. Lab. Med. 43: 470-479.
2. Maron, D. J., S. Fazio, and M. F. Linton. 2000. Current perspectives on statins. Circulation. 101: 207-213.
3. Hobbs, H. H., M. S. Brown, and J. L. Goldstein. 1992. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum. Mutat. 1: 445-466.
4. Schaefer, E. J., R. E. Gregg, G. Ghiselli, T. M. Forte, J. M. Ordavas, L. A. Zech, and H. B. Brewer, Jr. 1986. Familial apolipoprotein E deficiency. J. Clin. Invest. 78: 1206-1219.
5. Havekes, L., E. de Wit, J. G. Leuven, E. Klasen, G. Utermann, W. Weber, and U. Beisiegel. 1986. Apolipoprotein E3-Leiden. A new variant of human apolipoprotein E associated with familial type III hyperlipoproteinemia. Hum. Genet. 73: 157-163. (Pubitemid 16003754)
6. Ishibashi, S., M. S. Brown, J. L. Goldstein, R. D. Gerard, R. E. Hammer, and J. Herz. 1993. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J. Clin. Invest. 92: 883-893. (Pubitemid 23262411)
7. Plump, A. S., J. D. Smith, T. Hayek, K. Aalto-Setälä, A. Walsh, J. G. Verstuyft, E. M. Rubin, and J. L. Breslow. 1992. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 71: 343-353.
8. Zhang, S. H., R. L. Reddick, J. A. Piedrahita, and N. Maeda. 1992. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 258: 468-471.
9. van den Maagdenberg, A. M., M. H. Hofker, P. J. Krimpenfort, I. de Bruijn, B. van Vlijmen, H. van der Boom, L. M. Havekes, and R. R. Frants. 1993. Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia. J. Biol. Chem. 268: 10540-10545.
10. Westerterp, M., C. C. van der Hoogt, W. de Haan, E. H. Offerman, G. M. Dallinga-Thie, J. W. Jukema, L. M. Havekes, and P. C. Rensen. 2006. Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice. Arterioscler. Thromb. Vasc. Biol. 26: 2552-2559.
11. de Vries-van der Weij, J., S. Zadelaar, K. Toet, L. M. Havekes, T. Kooistra, and P. C. Rensen. 2009. Human CETP aggravates atherosclerosis by increasing VLDL-cholesterol rather than by decreasing HDL-cholesterol in APOE*3-Leiden mice. Atherosclerosis. 206: 153-158.
12. Elovson, J., J. E. Chatterton, G. T. Bell, V. N. Schumaker, M. A. Reuben, D. L. Puppione, J. R. Reeve, Jr., and N. L. Young. 1988. Plasma very low density lipoproteins contain a single molecule of apolipoprotein B. J. Lipid Res. 29: 1461-1473.
13. Brown, M. S., and J. L. Goldstein. 1986. A receptor-mediated pathway for cholesterol homeostasis. Science. 232: 34-47.
14. Davis, R. A., and T. Y. Hui. 2001. 2000 George Lyman Duff Memorial Lecture: atherosclerosis is a liver disease of the heart. Arterioscler. Thromb. Vasc. Biol. 21: 887-898.
15. Glueck, C. J., W. Kelley, A. Gupta, R. N. Fontaine, P. Wang, and P. S. Gartside. 1997. Prospective 10-year evaluation of hypobetalipoproteinemia in a cohort of 772 firefighters and cross-sectional evaluation of hypocholesterolemia in 1,479 men in the National Health and Nutrition Examination Survey I. Metabolism. 46: 625-633.
16. Tomari, Y., and P. D. Zamore. 2005. Perspective: machines for RNAi. Genes Dev. 19: 517-529.
17. Aagaard, L., and J. J. Rossi. 2007. RNAi therapeutics: principles, prospects and challenges. Adv. Drug Deliv. Rev. 59: 75-86.
18. Morrissey, D. V., K. Blanchard, L. Shaw, K. Jensen, J. A. Lockridge, B. Dickinson, J. A. McSwiggen, C. Vargeese, K. Bowman, C. S. Shaffer, et al. 2005. Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology. 41: 1349-1356. (Pubitemid 40770288)
19. Morrissey, D. V., J. A. Lockridge, L. Shaw, K. Blanchard, K. Jensen, W. Breen, K. Hartsough, L. Machemer, S. Radka, V. Jadhav, et al. 2005. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol. 23: 1002-1007. (Pubitemid 41114035)
20. Strapps, W. R., V. Pickering, G. T. Muiru, J. Rice, S. Orsborn, B. A. Polisky, A. B. Sachs, and S. R. Bartz. 2010. The siRNA sequence and guide strand overhangs are determinants of in vivo duration of silencing. Nucleic Acids Res. 38: 4788-4797.
21. Burchard, J., A. L. Jackson, V. Malkov, R. H. Needham, Y. Tan, S. R. Bartz, H. Dai, A. B. Sachs, and P. S. Linsley. 2009. MicroRNA-like off-target transcript regulation by siRNAs is species specific. RNA. 15: 308-315.
22. Abrams, M. T., M. L. Koser, J. Seitzer, S. C. Williams, M. A. DiPietro, W. Wang, A. W. Shaw, X. Mao, V. Jadhav, J. P. Davide, et al. 2010. Evaluation of efficacy, biodistribution, and inflammation for a potent siRNA nanoparticle: effect of dexamethasone co-treatment. Mol. Ther. 18: 171-180.
23. Bligh, E. G., and W. J. Dyer. 1959. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 37: 911-917.
24. Folch, J., M. Lees, and G. H. Sloane Stanley. 1957. A simple method for the isolation and purification of total lipids from animal tissues. J. Biol. Chem. 226: 497-509.
25. Burrier, R. E., A. A. Smith, D. G. McGregor, L. M. Hoos, D. L. Zilli, and H. R. Jr. Davis. 1995. The effect of acyl CoA: cholesterol acyltransferase inhibition on the uptake, esterification and secretion of cholesterol by the hamster small intestine. J. Pharmacol. Exp. Ther. 272: 156-163.
26. Wiklund, S., E. Johansson, L. Sjöström, E. J. Mellerowicz, U. Edlund, J. P. Shockcor, J. Gottfries, T. Moritz, and J. Trygg. 2008. Visualization of GC/TOF-MS-based metabolomics data for identifi cation of biochemically interesting compounds using OPLS class models. Anal. Chem. 80: 115-122. (Pubitemid 351448411)
27. Fahy, E., S. Subramaniam, H. A. Brown, C. K. Glass, A. H. Merrill, Jr., R. C. Murphy, C. R. Raetz, D. W. Russell, Y. Seyama, W. Shaw, et al. 2005. A comprehensive classification system for lipids. J. Lipid Res. 46: 839-861.
28. Castro-Perez, J. M., J. Kamphorst, J. DeGroot, F. Lafeber, J. Goshawk, K. Yu, J. P. Shockcor, R. J. Vreeken, and T. Hankemeier. 2010. Comprehensive LC-MS E lipidomic analysis using a shotgun approach and its application to biomarker detection and identification in osteoarthritis patients. J. Proteome Res. 9: 2377-2389.
29. Dai, M., P. Wang, A. D. Boyd, G. Kostov, B. Athey, E. G. Jones, W. E. Bunney, R. M. Myers, T. P. Speed, H. Akil, et al. 2005. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res. 33: e175.
30. Irizarry, R. A., B. M. Bolstad, F. Collin, L. M. Cope, B. Hobbs, and T. P. Speed. 2003. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 31: e15.
31. Greco, D., D. Leo, U. di Porzio, C. Perrone Capano, and P. Auvinen. 2008. Pre-filtering improves reliability of Affymetrix GeneChips results when used to analyze gene expression in complex tissues. Mol. Cell. Probes. 22: 115-121.
32. Harada, L. M., A. J. Carrilho, H. C. Oliveira, E. P. Nakandakare, and E. C. Quintão. 2006. Regulation of hepatic cholesterol metabolism in CETP/LDLr mice by cholesterol feeding and by drugs (cholestyramine and lovastatin) that lower plasma cholesterol. Clin. Exp. Pharmacol. Physiol. 33: 1209-1215.
33. Crooke, R. M., M. J. Graham, K. M. Lemonidis, C. P. Whipple, S. Koo, and R. J. Perera. 2005. An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J. Lipid Res. 46: 872-884.
34. Soutschek, J., A. Akinc, B. Bramlage, K. Charisse, R. Constien, M. Donoghue, S. Elbashir, A. Geick, P. Hadwiger, J. Harborth, et al. 2004. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature. 432: 173-178. (Pubitemid 39545841)
35. Zimmermann, T. S., A. C. Lee, A. Akinc, B. Bramlage, D. Bumcrot, M. N. Fedoruk, J. Harborth, J. A. Heyes, L. B. Jeffs, M. John, et al. 2006. RNAi-mediated gene silencing in non-human primates. Nature. 441: 111-114.
36. Lieu, H. D., S. K. Withycombe, Q. Walker, J. X. Rong, R. L. Walzem, J. S. Wong, R. L. Hamilton, E. A. Fisher, and S. G. Young. 2003. Eliminating atherogenesis in mice by switching off hepatic lipoprotein secretion. Circulation. 107: 1315-1321.
37. Cuchel, M., L. T. Bloedon, P. O. Szapary, D. M. Kolansky, M. L. Wolfe, A. Sarkis, J. S. Millar, K. Ikewaki, E. S. Siegelman, R. E. Gregg, et al. 2007. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N. Engl. J. Med. 356: 148-156. (Pubitemid 46089675)
38. Schonfeld, G., X. Lin, and P. Yue. 2005. Familial hypobetalipoproteinemia: genetics and metabolism. Cell. Mol. Life Sci. 62: 1372-1378. (Pubitemid 40853825)